Bempegaldesleukin-Opdivo Combo Leads to Prolonged Responses in TNBC Patients, Phase 1/2 Trial Shows

Bempegaldesleukin-Opdivo Combo Leads to Prolonged Responses in TNBC Patients, Phase 1/2 Trial Shows
Bempegaldesleukin (bempeg, NKTR-214) in combination with Opdivo (nivolumab) leads to prolonged treatment responses in women with advanced or metastatic triple-negative breast cancer (TNBC), a Phase 1/2 trial shows. The findings were presented in a poster titled, "Clinical activity of BEMPEG plus NIVO observed in metastatic TNBC: preliminary results from the TNBC cohort of the Ph1/2 PIVOT-02 study," at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, held Sept. 25-28 in Paris. Bempegaldesleukin, developed by Nektar Therapeutics, is an investigational first-in-class agent that targets CD122, a protein found on the surface of immune T cells and natural killer (NK) cells. It works by activating and stimulating the growth of these cancer-killing immune cells, without over-activating the entire immune system. PIVOT-02 (NCT02983045) is a multi-center, open-label, Phase 1/2 trial that is assessing the safety and efficacy of bempegaldesleukin in combination with Opdivo, an immune checkpoint inhibitor developed by Bristol-Myers Squibb, in patients with different types of solid cancers, including breast cancer. The study is divided into two phases: a dose escalation phase, in which patients with different types of solid cancers will be assigned to one of five different bempegaldesleukin-Opdivo combo regimens to determine the best dose and scheduling interval for each of the medications; and a dose expansion phase, in which patients with different types of solid cancers will receive bempegaldesleukin in combination with Opdivo at the best dose and scheduling interval determined during the dose escalation phase. During the conference, Nektar presented the first findings of the group of women with TNBC participating in the dose expansion phas
Subscribe or to access all post and page content.